ArticleJournal of diabetes investigation2026
Effect of sodium-glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims-based cohort study.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate the effect of sodium-glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission among older patients (≥75 years) with HF and diabetes and to compare the effectiveness of four SGLT2is, namely, ipragliflozin, empagliflozin, canagliflozin, and dapagliflozin, with a focus on direct head-to-head comparisons among individual SGLT2is. MATERIALS AND
methodsWe conducted a retrospective cohort study using the Medical Data Vision claims database. We included 66,895 patients aged ≥75 years who were emergently hospitalized for HF with comorbid diabetes between 2018 and 2022. Patients were categorized according to SGLT2i administration at discharge. Propensity score matching (PSM) was applied to adjust for baseline characteristics. The primary outcome was HF readmission, assessed using Kaplan-Meier analysis and Cox proportional hazards models. Inverse probability of treatment weighting (IPTW) was used to compare the four SGLT2is.
resultsAfter PSM, SGLT2i users showed a significantly lower risk of HF readmission than nonusers (hazard ratio [HR] 0.91, 95% confidence interval [CI]: 0.85-0.97, P = 0.003). Sensitivity analysis censoring death and treatment discontinuation or initiation produced consistent results (HR 0.79, 95% CI: 0.74-0.85, P < 0.001). An IPTW-based comparison of the four agents revealed no significant differences, suggesting similar class-wide effectiveness.
conclusionsAmong older patients with HF and diabetes, SGLT2i administration was associated with reduced HF readmission risk, with no meaningful differences among the four agents. These findings support a class-wide effect of SGLT2i and highlight the importance of their appropriate initiation and continuation in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.